Stocks
FDA Greenlights uniQure’s AMT-130 Data for Accelerated Approval Filing
uniQure's stock surged after the FDA indicated that three-year Phase I/II data for its Huntington's disease gene therapy, AMT-130, could support an...
uniQure's stock surged after the FDA indicated that three-year Phase I/II data for its Huntington's disease gene therapy, AMT-130, could support an...